Haematopoietic Stem Cell Transplantation (HSCT) in India – BMT
HSCT / Bone marrow transplant in India from $18,000. Autologous and allogeneic stem cell transplant for leukaemia, lymphoma, myeloma, thalassaemia, and aplastic anaemia. Top BMT centres.
Estimated cost: $18,000 – $40,000 · Average stay: 30–60 days
Haematopoietic stem cell transplantation (HSCT) — commonly known as bone marrow transplant (BMT) — replaces diseased or damaged bone marrow with healthy blood-forming stem cells. It is the most powerful treatment available for many haematological malignancies and inherited blood disorders.
India's dedicated BMT centres — at CMC Vellore, Tata Memorial Mumbai, AIIMS Delhi, Apollo Hospitals, and Fortis — perform over 2,000 transplants annually with internationally benchmarked outcomes. At $18,000–$40,000, India offers HSCT at 80–90% lower cost than the US ($200,000–$500,000).
Gaf Healthcare places patients at the centre best suited to their diagnosis, age, and clinical complexity, with comprehensive logistics support for the full 2–3 month stay.
What is Haematopoietic Stem Cell Transplantation?
HSCT uses high-dose chemotherapy (with or without total body irradiation) to destroy diseased bone marrow, then infuses healthy donor stem cells that home to the marrow and rebuild a new blood and immune system.
In autologous HSCT, the patient's own stem cells are collected before high-dose therapy, stored, and reinfused after conditioning — no rejection risk, no GVHD, but no graft-versus-tumour effect. In allogeneic HSCT, donor stem cells provide both marrow rescue and a graft-versus-tumour immune response — more powerful against cancer but with GVHD and rejection risks.
Stem cells are collected from peripheral blood via apheresis (most common), bone marrow harvest under general anaesthesia, or umbilical cord blood.
Who is Eligible for HSCT?
Autologous HSCT is used for multiple myeloma (standard of care for transplant-eligible patients), relapsed Hodgkin and non-Hodgkin lymphoma, and selected solid tumours. Allogeneic HSCT is used for acute leukaemia (ALL, AML), CML after TKI failure, myelodysplastic syndrome, aplastic anaemia, thalassaemia major, sickle cell disease, and inherited metabolic disorders. Age is not an absolute contraindication — reduced-intensity conditioning extends eligibility to older and less fit patients.
How is HSCT Performed?
Pre-transplant evaluation covers disease status, organ function (cardiac echo, PFTs, LFTs, renal function), HLA typing for allogeneic cases, and donor search (sibling, matched unrelated via DKMS/NMDP, or haploidentical). A Hickman or PICC central line is inserted.
Conditioning chemotherapy destroys disease and creates marrow space over 5–10 days. On transplant day (Day 0), stem cells are infused intravenously. Engraftment — rising white cells and platelets — occurs at days 10–21 (autologous) or days 14–30 (allogeneic). Post-transplant care includes G-CSF support, infection prophylaxis, and GVHD prophylaxis (allogeneic). Disease response and chimerism are assessed at days +28, +100.
Procedure Steps
- Disease reassessment: bone marrow biopsy, PET-CT/CT, MRD analysis before transplant
- Organ function baseline: echo, PFTs, LFTs, creatinine, dental and ophthalmic review
- HLA typing: high-resolution (4-field) typing of patient and all potential donors
- Central venous catheter insertion (Hickman line or PICC)
- Conditioning: myeloablative (busulfan-cyclophosphamide, TBI-etoposide) or RIC (fludarabine-melphalan)
- Stem cell infusion on Day 0: peripheral blood PBSC or bone marrow from donor
- Engraftment phase: daily CBC; G-CSF support; antimicrobial prophylaxis
- Allogeneic GVHD prophylaxis: calcineurin inhibitor + methotrexate or PTCy
- Day +28/+100: bone marrow biopsy, chimerism, MRD assessment
- Discharge planning: outpatient protocol, infection precautions, vaccination schedule
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $18,000 – $40,000 — Save 90%
UAE — $80,000 – $200,000 — Save 80%
United States — $200,000 – $500,000 — —
United Kingdom — $100,000 – $300,000 — —
Autologous HSCT in India costs $18,000–$25,000; allogeneic with sibling donor $25,000–$40,000. All figures include conditioning, stem-cell infusion, 30–60-day hospital stay, and initial post-transplant monitoring. India provides world-class HSCT at 80–90% lower cost than the US with equivalent outcomes.
Recovery & Follow-up
Autologous HSCT engraftment occurs at days 10–21; patients are typically discharged at day 21–28. Allogeneic HSCT engraftment takes 14–30 days; discharge typically at day 28–45. Fatigue, infection risk, and dietary restrictions are the main early challenges. Full immune reconstitution takes 6–12 months. Vaccination schedules are restarted from scratch.
Recovery Tips
- Follow all antimicrobial prophylaxis prescriptions precisely — the infection risk in the first 6 months is significant.
- Avoid raw or undercooked food for 3–6 months post-HSCT — food safety is essential during immunosuppression.
- Attend all chimerism, MRD, and organ function monitoring appointments.
- Report any fever above 38°C immediately — neutropenic fever requires urgent inpatient assessment.
- Wear sun protection — immunosuppression increases the risk of skin cancer with UV exposure.
Risks & Complications
Autologous HSCT risks: mucositis, infection during neutropenic period, engraftment failure (rare), and cardiotoxicity from conditioning. Allogeneic HSCT risks: GVHD (acute and chronic), rejection, CMV and other viral reactivation, and bacterial/fungal infections. Modern protocols reduce severe GVHD rates to under 20% in matched sibling transplants. Experienced BMT teams at India's premier centres manage all complications effectively.
Why GAF Healthcare
Gaf Healthcare selects the right Indian BMT centre for each patient's disease complexity, arranges accommodation and 24/7 support for families for the full 2–3 month stay, coordinates pre-transplant workup and HLA typing before travel to minimise time on-site, and prepares a comprehensive discharge protocol for post-transplant follow-up in the patient's home country.
Frequently Asked Questions
What is the difference between autologous and allogeneic HSCT?
Autologous uses your own stem cells — no rejection or GVHD risk. Allogeneic uses donor stem cells providing a graft-versus-tumour immune effect but with GVHD and rejection risks. Disease type determines which is appropriate.
What diseases are treated with HSCT in India?
Acute and chronic leukaemia, Hodgkin and non-Hodgkin lymphoma, multiple myeloma, aplastic anaemia, MDS, thalassaemia major, sickle cell disease, Fanconi anaemia, SCID, and rare inherited disorders.
How long will I need to stay in India?
30–60 days in hospital for conditioning, infusion, engraftment, and early monitoring, plus 30–60 days nearby before flying home. Total India stay is typically 2–3 months. We arrange full accommodation and support.
What is GVHD and how is it managed?
GVHD occurs when donor immune cells attack recipient tissues — skin, gut, liver. Acute GVHD is treated with corticosteroids. Modern prophylaxis reduces severe GVHD to under 20% in matched sibling transplants.
What are India's most reputable BMT centres?
CMC Vellore, Tata Memorial Hospital Mumbai, Apollo Hospitals Hyderabad and Chennai, Fortis Memorial Research Institute Gurgaon, and AIIMS Delhi are among India's premier BMT centres for international patients.